Literature DB >> 26345065

A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models.

Hayam Mohamed Ezz Eldin1, Hanan Hussein Kamel1, Abeer Fathy Badawy1, Lobna Sadek Shash2.   

Abstract

Toxoplasma gondii is an obligate intracellular protozoan that has a major importance in public health, in addition to veterinary medicine. Therefore, the development of an effective vaccine for controlling toxoplasmosis is an important goal. Excretory/secretory antigens (ESA), were previously identified as potential vaccine candidates, proved to play important roles in the pathogenesis and immune escape of the parasite. In addition, autoclaved Toxoplasma vaccine (ATV) is a special type of killed vaccine, recently characterized. The aim of the present work was, to compare between excretory/secretory and ATV against RH strain of T. gondii in mice based on; parasitological and histopathological levels. Tachyzoites were harvested from peritoneal exudates of infected mice and were used for challenge infection and vaccine preparation. BCG was used as an adjuvant. Mice were allocated equally into five groups; they were vaccinated intradermally over the sternum. The results of this study showed that the survival time after challenge, extended up to 16 days in ESA vaccinated group and up to 15 days in autoclaved Toxoplasma vaccinated group. ESA vaccinated group exhibited a profound decrease in parasite load following parasite challenge with a higher percentage of reduction in parasite count in all examined organs than the autoclaved Toxoplasma vaccinated group. The histopathological picture of the liver in both immunized groups, revealed marked reduction in the pathological changes observed as compared to controls, especially in ESA vaccinated group. It was concluded that vaccination with ESA showed more promising results versus ATV, as demonstrated by the survival rate of vaccinated mice, tachyzoites count and histopathological examination.

Entities:  

Keywords:  Autoclaved Toxoplasma vaccine; Excretory/secretory antigens; RH strain; Toxoplasma gondii

Year:  2013        PMID: 26345065      PMCID: PMC4554561          DOI: 10.1007/s12639-013-0390-6

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  51 in total

1.  Further studies on autoclaved cercarial vaccine against schistosomiasis: safety, longevity and stability.

Authors:  Maha M Eissa; Sonia R Allam; Mervat Z El-Azzouni; Hala R Maged; Iman S Dessouky
Journal:  J Egypt Soc Parasitol       Date:  2003-08

2.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

Review 3.  Veterinary vaccines against Toxoplasma gondii.

Authors:  Elisabeth A Innes; Paul M Bartley; Stephen Maley; Frank Katzer; David Buxton
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 4.  Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.

Authors:  E A Innes; A N Vermeulen
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

5.  Induction of protective Th1 immune responses in mice by vaccination with recombinant Toxoplasma gondii nucleoside triphosphate hydrolase-II.

Authors:  Feng Tan; Xin Hu; Fang-Jun Luo; Chang-Wang Pan; Xiao-Guang Chen
Journal:  Vaccine       Date:  2011-02-11       Impact factor: 3.641

6.  Toxoplasma gondii: protective immunity against experimental toxoplasmosis induced by a DNA vaccine encoding the perforin-like protein 1.

Authors:  Hai-Kuo Yan; Zi-Guo Yuan; Eskild Petersen; Xiu-Xiang Zhang; Dong-Hui Zhou; Quan Liu; Yong He; Rui-Qing Lin; Min-Jun Xu; Xu-Li Chen; Xiu-Ling Zhong; Xing-Quan Zhu
Journal:  Exp Parasitol       Date:  2011-02-15       Impact factor: 2.011

7.  Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model.

Authors:  Ahmad Daryani; Ahmad Zavaran Hosseini; Abdolhossein Dalimi
Journal:  Vet Parasitol       Date:  2003-04-18       Impact factor: 2.738

8.  Toxoplasmosis: the first commercial vaccine.

Authors:  D Buxton
Journal:  Parasitol Today       Date:  1993-09

Review 9.  Development of Toxoplasma gondii vaccine: A global challenge.

Authors:  Ramesh Verma; Pardeep Khanna
Journal:  Hum Vaccin Immunother       Date:  2012-10-30       Impact factor: 3.452

10.  Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii.

Authors:  G S Yap; T Scharton-Kersten; D J Ferguson; D Howe; Y Suzuki; A Sher
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more
  3 in total

1.  Remarkable histopathological improvement of experimental toxoplasmosis after receiving spiramycin-chitosan nanoparticles formulation.

Authors:  Amal Farahat Allam; Nancy Abd-Elkader Hagras; Hoda Fahmy Farag; Mervat Mostafa Osman; Thanaa Ibrahim Shalaby; Amani Hussein Kazem; Amel Youssef Shehab; Nermine Mogahed Fawzy Hussein Mogahed
Journal:  J Parasit Dis       Date:  2021-08-10

2.  A Lactate Fermentation Mutant of Toxoplasma Stimulates Protective Immunity Against Acute and Chronic Toxoplasmosis.

Authors:  Ningbo Xia; Taifang Zhou; Xiaohan Liang; Shu Ye; Pengfei Zhao; Jichao Yang; Yanqin Zhou; Junlong Zhao; Bang Shen
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

3.  Immunoinformatic analysis of immunogenic B- and T-cell epitopes of MIC4 protein to designing a vaccine candidate against Toxoplasma gondii through an in-silico approach.

Authors:  Ali Dalir Ghaffari; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Majid Pirestani; Hamidreza Majidiani
Journal:  Clin Exp Vaccine Res       Date:  2021-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.